Single User License
INR 128440
Site License
INR 256880
Corporate User License
INR 385320

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Actinic (Solar) Keratosis-Pipeline Review, H1 2017

Actinic (Solar) Keratosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9172IDB
  • |
  • Pages: 64
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Actinic (Solar) Keratosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis-Pipeline Review, H1 2017, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.

An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 1, 6, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Actinic (Solar) Keratosis-Overview

Actinic (Solar) Keratosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Actinic (Solar) Keratosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Actinic (Solar) Keratosis-Companies Involved in Therapeutics Development

3M Drug Delivery Systems

Athenex Inc

CritiTech Inc

Foamix Pharmaceuticals Ltd

G&E Herbal Biotechnology Co Ltd

Galderma SA

Laboratories Ojer Pharma SL

LEO Pharma A/S

Novartis AG

Oncology Research International Ltd

Promius Pharma LLC

Valeant Pharmaceuticals International Inc

Vectura Group Plc

Actinic (Solar) Keratosis-Drug Profiles

854-A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACT-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-17137-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

celecoxib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFD-08-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-695-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrogen peroxide + sulindac-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDP-125-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDP-128-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ingenol disoxate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LFX-453-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORIL-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paclitaxel-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKP-024-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VDA-1102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Actinic (Solar) Keratosis-Dormant Projects

Actinic (Solar) Keratosis-Discontinued Products

Actinic (Solar) Keratosis-Product Development Milestones

Featured News & Press Releases

Dec 12, 2016: Vidac Pharma Phase 2 Study Of VDA-1102 In Actinic Keratosis Meets Interim Analysis Criterion

Jul 29, 2016: Vidac Pharma Announces The Innitiation Of A Phase 2 Study Of VDA-1102 Ointment In Patients With Actinic Keratosis

Jun 30, 2016: Vidac Pharma Completes Phase 1A Trial Of VDA-1102 Ointment

Feb 25, 2016: Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Dec 30, 2015: Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis

Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Actinic (Solar) Keratosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Actinic (Solar) Keratosis-Pipeline by 3M Drug Delivery Systems, H1 2017

Actinic (Solar) Keratosis-Pipeline by Athenex Inc, H1 2017

Actinic (Solar) Keratosis-Pipeline by CritiTech Inc, H1 2017

Actinic (Solar) Keratosis-Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Actinic (Solar) Keratosis-Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017

Actinic (Solar) Keratosis-Pipeline by Galderma SA, H1 2017

Actinic (Solar) Keratosis-Pipeline by Laboratories Ojer Pharma SL, H1 2017

Actinic (Solar) Keratosis-Pipeline by LEO Pharma A/S, H1 2017

Actinic (Solar) Keratosis-Pipeline by Novartis AG, H1 2017

Actinic (Solar) Keratosis-Pipeline by Oncology Research International Ltd, H1 2017

Actinic (Solar) Keratosis-Pipeline by Promius Pharma LLC, H1 2017

Actinic (Solar) Keratosis-Pipeline by Valeant Pharmaceuticals International Inc, H1 2017

Actinic (Solar) Keratosis-Pipeline by Vectura Group Plc, H1 2017

Actinic (Solar) Keratosis-Dormant Projects, H1 2017

Actinic (Solar) Keratosis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Actinic (Solar) Keratosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3M Drug Delivery Systems, Athenex Inc, CritiTech Inc, Foamix Pharmaceuticals Ltd, G&E Herbal Biotechnology Co Ltd, Galderma SA, Laboratories Ojer Pharma SL, LEO Pharma A/S, Novartis AG, Oncology Research International Ltd, Promius Pharma LLC, Valeant Pharmaceuticals International Inc, Vectura Group Plc


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com